Angela Patrick, APRN
Adult Health · Oklahoma City, OKNPI 1437330545
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,967 of the $2,699 with a category attached, or 72.9%. 14 manufacturers reported payments, led by Abbott at 48.5% of the total. Reporting peaked in 2023 at $1,470 and has fallen 80.1% since, to $292 in 2025.
Across 83 payments — averaging $32.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Pfizer$224
- Impulse Dynamics (USA) Inc.$166
- Alnylam Pharmaceuticals Inc.$151
- Merck$147
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$131
- plus $571 from 8 others
What the payments were for
- Travel & lodging$73227%
- Food & beverage$1,96773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 24 | $1,309 |
| Pfizer | 9 | $224 |
| Impulse Dynamics (USA) Inc. | 8 | $166 |
| Alnylam Pharmaceuticals Inc. | 7 | $151 |
| Merck | 7 | $147 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $131 |
| Kestra Medical Technology Services, Inc. | 5 | $130 |
| AstraZeneca | 2 | $91 |
| Sage Therapeutics, LLC | 1 | $91 |
| Exelixis Inc. | 3 | $73 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Boehringer Ingelheim | 3 | $55 |
| Cvrx, Inc. | 2 | $40 |
| Boston Scientific | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,699 in reported general payments places this provider in the 75th percentile of 117 adult health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 167 | $166,629 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $60,028 |
| EliquisApixaban | 56 | $52,271 |
| JardianceEmpagliflozin | 52 | $46,755 |
| FarxigaDapagliflozin Propanediol | 32 | $31,287 |
| Mycophenolate Mofetil | 23 | $5,747 |
| Metoprolol Succinate | 143 | $3,766 |
| VascepaIcosapent Ethyl | 11 | $3,669 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 12 | $3,587 |
| Clonidine | 14 | $3,150 |
| Tacrolimus | 44 | $3,013 |
| Potassium Chloride | 112 | $2,561 |
| Torsemide | 98 | $2,314 |
| Atorvastatin Calcium | 62 | $1,755 |
| Warfarin Sodium | 90 | $1,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $224 | $52,27156 claims |
| Boehringer IngelheimJardiance | $55 | $46,75552 claims |
| AstraZenecaFarxiga | $91 | $31,28732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 adult health providers in Oklahoma.
Other adult health in Oklahoma City
- Cynthia CattaneoOklahoma City$45K
- Miki ThompsonOklahoma City$14K
- Kellie RohwerOklahoma City$11K
- Terry GreenOklahoma City$9K
- Nissy PhilipOklahoma City$8K
- Alexis StinnettOklahoma City$6K
- Michael EskewOklahoma City$5K
- Candace BeckerOklahoma City$5K
- Anna CottleOklahoma City$5K
- Tyler AgeeOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.